These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 6164969)

  • 1. [Yellow fever antibodies in gamma globulin preparations after vaccination. Determination using simple neutralization tests on cultured cells].
    Huber HC; Hochstein-Mintzel V; Ritter U
    Offentl Gesundheitswes; 1981 Apr; 43(4):191-4. PubMed ID: 6164969
    [No Abstract]   [Full Text] [Related]  

  • 2. Yellow fever outbreak in Ipetu-Ijesa: response after mass vaccination.
    Adu FD; Adeniji JA; Tomori O; Adelasoye A
    Rev Roum Virol; 1993; 44(1-2):3-7. PubMed ID: 8043476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of MAC-ELISA for evaluation of yellow fever vaccination.
    Nogueira RM; Schatzmayr HG; Miagostovich MP; Cavalcanti SM; de Carvalho R
    Rev Inst Med Trop Sao Paulo; 1992; 34(5):447-50. PubMed ID: 1342109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?
    Barrett AD; Teuwen DE
    Curr Opin Immunol; 2009 Jun; 21(3):308-13. PubMed ID: 19520559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The standardization of the plaque reduction technic for differentiating a dengue infection from a yellow fever infection].
    Alvarez Vera M; Valdés Palacios D; Vázquez Ramudo S; Delgado Hernández I; García Infante S; Morier Díaz L; Guzmán Tirado MG
    Rev Cubana Med Trop; 1998; 50(3):177-81. PubMed ID: 10349439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vaccination against yellow fever].
    Acar JF
    Presse Med (1893); 1967 Sep; 75(40):1961-2. PubMed ID: 6061852
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients.
    Veit O; Niedrig M; Chapuis-Taillard C; Cavassini M; Mossdorf E; Schmid P; Bae HG; Litzba N; Staub T; Hatz C; Furrer H;
    Clin Infect Dis; 2009 Mar; 48(5):659-66. PubMed ID: 19191654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program.
    Collaborative Group for Studies with Yellow Fever Vaccine
    Vaccine; 2007 Apr; 25(16):3118-23. PubMed ID: 17316925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru.
    Belmusto-Worn VE; Sanchez JL; McCarthy K; Nichols R; Bautista CT; Magill AJ; Pastor-Cauna G; Echevarria C; Laguna-Torres VA; Samame BK; Baldeon ME; Burans JP; Olson JG; Bedford P; Kitchener S; Monath TP
    Am J Trop Med Hyg; 2005 Feb; 72(2):189-97. PubMed ID: 15741556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Content of antibodies to certain cardiotropic strains of enteral viruses in commercial gamma-globulin preparations].
    Venediktova NIa; Khovanova AM; Kolpakova VE; Patsuk NV; Deĭch SB
    Zh Mikrobiol Epidemiol Immunobiol; 1975 Aug; (8):147-8. PubMed ID: 53971
    [No Abstract]   [Full Text] [Related]  

  • 11. [Results of anti-yellow fever vaccination campaigns in the Central Africa Republic].
    Chippaux A; Chippaux-Hyppolite C
    Bull Soc Pathol Exot Filiales; 1966; 59(1):42-52. PubMed ID: 6012576
    [No Abstract]   [Full Text] [Related]  

  • 12. [Observations on the 17 D virus vaccine against yellow fever, applied by cutaneous scarification].
    Groot H; Gast-Galvis A
    Rev Invest (Guadalajara); 1965 Apr; 5(1):5-25. PubMed ID: 5829925
    [No Abstract]   [Full Text] [Related]  

  • 13. Heterotypic serologic responses after yellow fever vaccination; detection of persons with past St. Louis encephalitis or dengue.
    Pond WL; Ehrenkranz NJ; Danauskas JX; Carter MJ
    J Immunol; 1967 Apr; 98(4):673-82. PubMed ID: 6022887
    [No Abstract]   [Full Text] [Related]  

  • 14. [Content of viral antibodies and tetanus antitoxin in human gamma globulin Dessau].
    Glathe H; Klett G; Thilo W
    Dtsch Gesundheitsw; 1973; 28(5):204-8. PubMed ID: 4124702
    [No Abstract]   [Full Text] [Related]  

  • 15. [Anti-yellow fever vaccination].
    Finelli L
    Acta Med Ital Med Trop Subtrop Gastroenterol; 1963 Oct; 18(10):303-11. PubMed ID: 5173845
    [No Abstract]   [Full Text] [Related]  

  • 16. [Prevalence of yellow fever antibodies in north Zaire].
    Werner GT; Huber HC; Fresenius K
    Ann Soc Belg Med Trop; 1985; 65(1):91-3. PubMed ID: 4004378
    [No Abstract]   [Full Text] [Related]  

  • 17. [Vaccination against yellow fever].
    Rasmussen MK
    Ugeskr Laeger; 1992 Jan; 154(4):215-6. PubMed ID: 1736453
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial.
    Pfister M; Kürsteiner O; Hilfiker H; Favre D; Durrer P; Ennaji A; L'Age-Stehr J; Kaufhold A; Herzog C
    Am J Trop Med Hyg; 2005 Mar; 72(3):339-46. PubMed ID: 15772332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Level of antibodies in human gamma-globulin preparations.
    Stárek M; Mazácek M; Kyselová M; Babková H
    Prog Immunobiol Stand; 1970; 4():126-8. PubMed ID: 4098253
    [No Abstract]   [Full Text] [Related]  

  • 20. Yellow fever outbreak in Ipetu-Ijesa: response after mass vaccination.
    Adu FD; Adeniji JA; Tomori O; Adelasoye A
    Rom J Virol; 1993; 44(1-2):3-7. PubMed ID: 9702244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.